BCL-2 Proteins and their Role in Cancer Resistance
Authors:
- 22 March 2017
- book chapter
- Published by Springer Nature
- p. 475-482
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer TherapeuticsCancer Discovery, 2015
- Control of apoptosis by the BCL-2 protein family: implications for physiology and therapyNature Reviews Molecular Cell Biology, 2013
- Combination Treatments with the PKC Inhibitor, Enzastaurin, Enhance the Cytotoxicity of the Anti-Mesothelin Immunotoxin, SS1PPLOS ONE, 2013
- BH3 Mimetics: Status of the Field and New DevelopmentsMolecular Cancer Therapeutics, 2013
- Combination treatments with ABT‐263 and an immunotoxin produce synergistic killing of ABT‐263‐resistant small cell lung cancer cell linesInternational Journal of Cancer, 2012
- ABT-737 Synergizes with Chemotherapy to Kill Head and Neck Squamous Cell Carcinoma Cells via a Noxa-Mediated PathwayMolecular Pharmacology, 2009
- Differential Targeting of Prosurvival Bcl-2 Proteins by Their BH3-Only Ligands Allows Complementary Apoptotic FunctionMolecular Cell, 2005
- Subversion of the Bcl-2 Life/Death Switch in Cancer Development and TherapyCold Spring Harbor Symposia on Quantitative Biology, 2005
- Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeuticsCancer Cell, 2002
- Identification of Novel Isoforms of the BH3 Domain Protein Bim Which Directly Activate Bax To Trigger ApoptosisMolecular and Cellular Biology, 2002